Neurizon Therapeutics Ltd

NEW
FRA:ECQ0 (Australia)  
€ 0.033 (0%) Jul 3
At Loss
P/B:
4.67
Market Cap:
€ 32.35M ($ 37.02M)
Enterprise V:
€ 28.54M ($ 32.66M)
Volume:
0
Avg Vol (2M):
10.00K
Trade In:

Business Description

Description
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
4.89
Equity-to-Asset
0.54
Debt-to-Equity
0.2
Debt-to-EBITDA
-0.11
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
-109.9
3-Year EPS without NRI Growth Rate
-87.6
3-Year FCF Growth Rate
-93.5
3-Year Book Growth Rate
-37

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
66.18
9-Day RSI
57.34
14-Day RSI
52.64
3-1 Month Momentum %
-31.71
6-1 Month Momentum %
-33.33
12-1 Month Momentum %
-68.89

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
2.18
Quick Ratio
2.18
Cash Ratio
1.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-15.8
Shareholder Yield %
-20.1

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-193.59
ROA %
-126.48
ROIC %
-2707.4
3-Year ROIIC %
226.58
ROC (Joel Greenblatt) %
-1491.06
ROCE %
-193.44
Moat Score
2

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
4.67
Price-to-Tangible-Book
3.25
EV-to-EBIT
-3.17
EV-to-EBITDA
-3.18
EV-to-FCF
-2.7
Price-to-Net-Current-Asset-Value 3.25
Earnings Yield (Greenblatt) %
-31.55
FCF Yield %
-32.66

Financials

FRA:ECQ0's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Neurizon Therapeutics Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.016
Beta 1.616
3-Year Sharpe Ratio 0.37
3-Year Sortino Ratio 0.66
Volatility % 92.19
14-Day RSI 52.64
14-Day ATR (€) 0.002161
20-Day SMA (€) 0.0305
12-1 Month Momentum % -68.89
52-Week Range (€) 0.026 - 0.097
Shares Outstanding (Mil) 763.64

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Neurizon Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Neurizon Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (€)
0.05:1 Stock Split 2015-10-30 0.02 (+0.00%)
Show
Entries

Neurizon Therapeutics Ltd Frequently Asked Questions

What is Neurizon Therapeutics Ltd(FRA:ECQ0)'s stock price today?
The current price of FRA:ECQ0 is €0.03. The 52 week high of FRA:ECQ0 is €0.10 and 52 week low is €0.03.
When is next earnings date of Neurizon Therapeutics Ltd(FRA:ECQ0)?
The next earnings date of Neurizon Therapeutics Ltd(FRA:ECQ0) is .
Does Neurizon Therapeutics Ltd(FRA:ECQ0) pay dividends? If so, how much?
Neurizon Therapeutics Ltd(FRA:ECQ0) does not pay dividend.

Articles on Neurizon Therapeutics Ltd

No articles.